Real-world Data on the Efficacy and Safety of Ixazomib-based Therapy in Multiple Myeloma: A Single-center Study in China
作者： Kai Ding , Hong Yu , Yuan-Yuan Shao , Li-Yan Li , Chao-Meng Wang
DOI: 10.2147/CMAR.S261887
关键词:
摘要: Objective To assess the short-term efficacy and safety of ixazomib in Chinese multiple myeloma (MM) patients real world. Methods Fifty-nine MM who received at least one cycle ixazomib-based therapy between 1 June 2018 30 September 2019 were retrospectively analyzed Tianjin Medical University General Hospital. Thirteen newly diagnosed (NDMM), 13 refractory/relapsed (RRMM) 33 continuous (27 bortezomib peripheral neuritis (PN) intolerant six maintenance therapy) included. The indicated overall response rate (ORR), time to (TOR), adverse events (AEs) investigated. Results ORR NDMM was 76.9%, with complete (CR), five very good partial (VGPR), four (PR), median PFS, TOR 122 (66-272) days 49 (22-108) days. RRMM 46.2%, CR, two VGPR, three PR, 79 (28-169) 59 (23-88) 100%, nine stringent 15 VGPR 75 (25-141) There no significant differences regarding cytogenetic high risk standard subgroups (all P>0.05). most frequent hematological AEs anemia (13.6%) thrombocytopenia (10.2%). common nonhematological PN (25.0%) diarrhea (13.6%). Conclusion real-world data demonstrated that generally effective safe short term for patients.
scilit.net参考文章(23)
Marta Morawska, Norbert Grzasko, Magdalena Kostyra, Jolanta Wojciechowicz, Marek Hus, Therapy‐related peripheral neuropathy in multiple myeloma patients Hematological Oncology. ,vol. 33, pp. 113- 119 ,(2015) , 10.1002/HON.2149
Meletios Dimopoulos, Andrew Spencer, Michael Attal, H. Miles Prince, Jean-Luc Harousseau, Anna Dmoszynska, Jesus San Miguel, Andrzej Hellmann, Thierry Facon, Robin Foà, Alessandro Corso, Zvenyslava Masliak, Marta Olesnyckyj, Zhinuan Yu, John Patin, Jerome B. Zeldis, Robert D. Knight, Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma The New England Journal of Medicine. ,vol. 357, pp. 2123- 2132 ,(2007) , 10.1056/NEJMOA070594
S K Kumar, A Dispenzieri, M Q Lacy, M A Gertz, F K Buadi, S Pandey, P Kapoor, D Dingli, S R Hayman, N Leung, J Lust, A McCurdy, S J Russell, S R Zeldenrust, R A Kyle, S V Rajkumar, Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients Leukemia. ,vol. 28, pp. 1122- 1128 ,(2014) , 10.1038/LEU.2013.313
K C Anderson, , R A Kyle, S V Rajkumar, A K Stewart, D Weber, P Richardson, Clinically relevant end points and new drug approvals for myeloma. Leukemia. ,vol. 22, pp. 231- 239 ,(2008) , 10.1038/SJ.LEU.2405016
Shaji K Kumar, Jesus G Berdeja, Ruben Niesvizky, Sagar Lonial, Jacob P Laubach, Mehdi Hamadani, A Keith Stewart, Parameswaran Hari, Vivek Roy, Robert Vescio, Jonathan L Kaufman, Deborah Berg, Eileen Liao, Alessandra Di Bacco, Jose Estevam, Neeraj Gupta, Ai-Min Hui, Vincent Rajkumar, Paul G Richardson, Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study Lancet Oncology. ,vol. 15, pp. 1503- 1512 ,(2014) , 10.1016/S1470-2045(14)71125-8
Dharminder Chauhan, Ze Tian, Bin Zhou, Deborah Kuhn, Robert Orlowski, Noopur Raje, Paul Richardson, Kenneth C. Anderson, In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells Clinical Cancer Research. ,vol. 17, pp. 5311- 5321 ,(2011) , 10.1158/1078-0432.CCR-11-0476
Erik Kupperman, Edmund C. Lee, Yueying Cao, Bret Bannerman, Michael Fitzgerald, Allison Berger, Jie Yu, Yu Yang, Paul Hales, Frank Bruzzese, Jane Liu, Jonathan Blank, Khristofer Garcia, Christopher Tsu, Larry Dick, Paul Fleming, Li Yu, Mark Manfredi, Mark Rolfe, Joe Bolen, Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer Cancer Research. ,vol. 70, pp. 1970- 1980 ,(2010) , 10.1158/0008-5472.CAN-09-2766
Laurent Garderet, Simona Iacobelli, Philippe Moreau, Mamoun Dib, Ingrid Lafon, Dietger Niederwieser, Tamas Masszi, Jean Fontan, Mauricette Michallet, Alois Gratwohl, Giuseppe Milone, Chantal Doyen, Brigitte Pegourie, Roman Hajek, Philippe Casassus, Brigitte Kolb, Carine Chaleteix, Bernd Hertenstein, Francesco Onida, Heinz Ludwig, Nicolas Ketterer, Christian Koenecke, Marleen van Os, Mohamad Mohty, Andrew Cakana, Norbert Claude Gorin, Theo de Witte, Jean Luc Harousseau, Curly Morris, Gösta Gahrton, Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation Journal of Clinical Oncology. ,vol. 30, pp. 2475- 2482 ,(2012) , 10.1200/JCO.2011.37.4918
Philippe Moreau, Tamás Masszi, Norbert Grzasko, Nizar J Bahlis, Markus Hansson, Ludek Pour, Irwindeep Sandhu, Peter Ganly, Bartrum W Baker, Sharon R Jackson, Anne-Marie Stoppa, David R Simpson, Peter Gimsing, Antonio Palumbo, Laurent Garderet, Michele Cavo, Shaji Kumar, Cyrille Touzeau, Francis K Buadi, Jacob P Laubach, Deborah T Berg, Jianchang Lin, Alessandra Di Bacco, Ai-Min Hui, Helgi van de Velde, Paul G Richardson, None, Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma The New England Journal of Medicine. ,vol. 374, pp. 1621- 1634 ,(2016) , 10.1056/NEJMOA1516282
Shaji Kumar, Bruno Paiva, Kenneth C Anderson, Brian Durie, Ola Landgren, Philippe Moreau, Nikhil Munshi, Sagar Lonial, Joan Bladé, Maria-Victoria Mateos, Meletios Dimopoulos, Efstathios Kastritis, Mario Boccadoro, Robert Orlowski, Hartmut Goldschmidt, Andrew Spencer, Jian Hou, Wee Joo Chng, Saad Z Usmani, Elena Zamagni, Kazuyuki Shimizu, Sundar Jagannath, Hans E Johnsen, Evangelos Terpos, Anthony Reiman, Robert A Kyle, Pieter Sonneveld, Paul G Richardson, Philip McCarthy, Heinz Ludwig, Wenming Chen, Michele Cavo, Jean-Luc Harousseau, Suzanne Lentzsch, Jens Hillengass, Antonio Palumbo, Alberto Orfao, S Vincent Rajkumar, Jesus San Miguel, Herve Avet-Loiseau, International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma The Lancet Oncology. ,vol. 17, pp. e328- e346 ,(2016) , 10.1016/S1470-2045(16)30206-6